Myriad Genetics, Inc. Common Stock MYGN
i
Market dataready · fetched 2026-11-12T03:23:17.090Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:29:31.463748521Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:19:52.514418+00:00
Myriad Genetics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.05 | 85.7% | 11.7% | |||
| 25Δ | 5.14 | 84.4% | 10.7% | |||
| 30Δ | 9.67 | 414.2% | 81.5% | 5.24 | 83.2% | 9.8% |
| 35Δ | 5.33 | 81.9% | 8.8% | |||
| 40Δ | 5.90 | 105.9% | 9.9% | 5.43 | 80.6% | 7.8% |
| 45Δ | 5.76 | 113.3% | 9.1% | 5.53 | 79.3% | 6.8% |
| 50Δ | 5.62 | 120.6% | 8.3% | 5.62 | 78.0% | 5.8% |
| 55Δ | 5.49 | 128.0% | 7.5% | 5.72 | 76.7% | 4.9% |
| 60Δ | 5.35 | 135.4% | 6.7% | 5.81 | 75.5% | 3.9% |
| 65Δ | 5.21 | 142.7% | 5.9% | 5.91 | 74.2% | 2.9% |
| 70Δ | 5.07 | 150.1% | 5.1% | 6.01 | 73.1% | 2.0% |
| 75Δ | 4.85 | 161.7% | 4.3% | |||
| 80Δ | 4.55 | 177.7% | 3.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.05
- IV
- 85.7%
- B/E move
- 11.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.14
- IV
- 84.4%
- B/E move
- 10.7%
30Δ
- Pseudo strike
- 9.67
- IV
- 414.2%
- B/E move
- 81.5%
- Pseudo strike
- 5.24
- IV
- 83.2%
- B/E move
- 9.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.33
- IV
- 81.9%
- B/E move
- 8.8%
40Δ
- Pseudo strike
- 5.90
- IV
- 105.9%
- B/E move
- 9.9%
- Pseudo strike
- 5.43
- IV
- 80.6%
- B/E move
- 7.8%
45Δ
- Pseudo strike
- 5.76
- IV
- 113.3%
- B/E move
- 9.1%
- Pseudo strike
- 5.53
- IV
- 79.3%
- B/E move
- 6.8%
50Δ
- Pseudo strike
- 5.62
- IV
- 120.6%
- B/E move
- 8.3%
- Pseudo strike
- 5.62
- IV
- 78.0%
- B/E move
- 5.8%
55Δ
- Pseudo strike
- 5.49
- IV
- 128.0%
- B/E move
- 7.5%
- Pseudo strike
- 5.72
- IV
- 76.7%
- B/E move
- 4.9%
60Δ
- Pseudo strike
- 5.35
- IV
- 135.4%
- B/E move
- 6.7%
- Pseudo strike
- 5.81
- IV
- 75.5%
- B/E move
- 3.9%
65Δ
- Pseudo strike
- 5.21
- IV
- 142.7%
- B/E move
- 5.9%
- Pseudo strike
- 5.91
- IV
- 74.2%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 5.07
- IV
- 150.1%
- B/E move
- 5.1%
- Pseudo strike
- 6.01
- IV
- 73.1%
- B/E move
- 2.0%
75Δ
- Pseudo strike
- 4.85
- IV
- 161.7%
- B/E move
- 4.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 4.55
- IV
- 177.7%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 157.65% | |
| 124.53% | |
| 111.31% | |
| 121.62% | |
| 125.30% | |
| 121.42% | |
| 89.73% | |
| 99.44% | |
| 120.13% |
Diagnostics & Research
NEO
Description unavailable
More →NTRA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
More →OPK
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and…
More →PSNL
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
More →QGEN
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
More →RDNT
Description unavailable
More →